Cerdulatinib

Drug Profile

Cerdulatinib

Alternative Names: Dual SYK/JAK inhibitor - Portola; PRT 2070; PRT-062070; RVT-502; RVT-502 - Dermavant Sciences

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Dermavant Sciences; NicOx; Portola Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Eye disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Skin disorders
  • No development reported Allergic rhinitis; Eye disorders

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in Skin disorders in Switzerland (Topical) before January 2017 (Roivant Sciences pipeline, January 2017)
  • 21 Dec 2016 Dermavant Sciences in-licenses topical formulations of cerdulatinib from Portola Pharmaceuticals for skin disorders
  • 21 Dec 2016 Preclinical trials in Skin disorders in Switzerland (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top